Can we safely reduce the number of days of radiotherapy needed to treat people with breast cancer who need boost treatment?

Submission date	Recruitment status	[X] Prospectively registered	
19/02/2025	Recruiting	☐ Protocol	
Registration date	Overall study status	Statistical analysis plan	
03/03/2025	Ongoing Condition category	☐ Results	
Last Edited		Individual participant data	
03/03/2025	Cancer	[X] Record updated in last year	

Plain English summary of protocol

Background and study aims

Each year, 37,000 people in the UK with breast cancer receive radiotherapy, which uses radiation to kill cancer cells. Most people can now be treated over 5 days, but about 10,000 still need up to 23 days of treatment because they require an extra dose called a boost. This study aims to find out if the boost can be given within a 5-day radiotherapy course, comparing two different boost doses over 5 days with the standard 15-day boost dose.

Who can participate?

People with breast cancer who need a boost dose as part of their radiotherapy treatment can participate. Participants will be invited from 50 UK radiotherapy centres.

What does the study involve?

Participants will be randomly placed into one of three groups by a computer:

One group will receive the boost dose over 15 days.

Two groups will receive the boost dose over 5 days, with different boost doses for each group. Participants will provide information about side effects, changes to the treated breast, extreme tiredness, and quality of life for five years.

What are the possible benefits and risks of participating? The study aims to show that the 5-day treatment is as effective as the 15-day treatment in preventing cancer from returning, with the same or fewer side effects and faster recovery. Risks include potential side effects from radiotherapy and the possibility that the shorter treatment may not be as effective.

Where is the study run from?

Institute of Cancer Research - Clinical Trials and Statistics Unit (UK).

When is the study starting and how long is it expected to run for? April 2025 to September 2033

Who is funding the study?

The study is funded by the National Institute for Health and Care Research - Health Technology Assessment (NIHR-HTA) programme (UK).

Who is the main contact? Institute of Cancer Research - Clinical Trials and Statistics Unit fastforwardboost-icrctsu@icr.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Judith Bliss

Contact details

ICR-CTSU,
Sir Richard Doll Building,
The Institute of Cancer Research,
Cotswold Road
Sutton
United Kingdom
SM2 5NG
+44 208 722 4104
Fastforwardboost-icrctsu@icr.ac.uk

Type(s)

Principal investigator

Contact name

Dr Anna Kirby

ORCID ID

https://orcid.org/0000-0002-5528-1669

Contact details

Royal Marsden Hospital Downs Road Sutton United Kingdom SM2 5PT +44 2087224104 anna.kirby@rmh.nhs.uk

Type(s)

Public

Contact name

Mr Mark Sydenham

ORCID ID

https://orcid.org/0000-0002-9157-9710

Contact details

ICR-CTSU,
Sir Richard Doll Building,
The Institute of Cancer Research,
Cotswold Road
Sutton
United Kingdom
SM2 5NG
+44 208 722 4104
fastforwardboost-icrctsu@icr.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

341881

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 57885, NIHR157800, ICR_CTSU/2024/10088

Study information

Scientific Title

A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost radiotherapy against a standard 3-week schedule in patients with early breast cancer

Acronym

FAST-Forward Boost

Study objectives

Local recurrence rates at 5-years will be no higher with appropriately dosed 1-week Simultaneous Integrated Boost radiotherapy (SIB RT) than with 3-week SIB radiotherapy and that this can be achieved without an increase in normal tissue side-effects

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 14/01/2025, London - South East REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8222; londonsoutheast.rec@hra.nhs.uk), ref: 24/LO/0910

Study design

Phase III multi-centre randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Patients will be treated using standard radiotherapy to the breast +/- nodes with a SIB to the tumour bed and randomised on a 1:1:1 basis to one of the following schedules:

- Standard radiotherapy to the breast +/- nodes using a schedule of 40Gy/15Fr over 3 weeks with a 48Gy/15Fr simultaneous integrated boost (SIB) of the tumour bed (Control Group)
- 26Gy/5Fr over 1 week with a 31Gy/5Fr SIB (Test Group 1)
- 26Gy/5Fr over 1 week with a 30Gy/5Fr SIB (Test Group 2)

Radiotherapy treatment

All patients will attend the radiotherapy department for a planning CT scan so their radiotherapy treatment can be planned.

Once the treatment has been planned. The patient will start their radiotherapy treatment. Treatment is usually given daily on week days. Those in the control group will have their radiotherapy treatment in 15 treatments, the test groups will have their radiotherapy in 5 treatments.

Questionnaires

For those taking part in the early side-effects sub-study, questionnaires about side-effects will need to be completed by the patient prior to radiotherapy, weekly for 7 weeks from start of radiotherapy and at 3 months.

All patients will be asked to complete questionnaire booklets pre treatment and at weeks 1, 3 and 5 from the start of radiotherapy then at 3 months, 1, 2, 3, 4 and 5 years.

Follow up

For those taking part in the early side-effects sub-study:

Control group: will also be reviewed at weeks 1, 3, 5 and 7 from the start of radiotherapy Test Groups: will also be reviewed at weeks 1, 3, 5 and 7 from the start of radiotherapy All patients will be reviewed by the clinical team at 3 months, 1 years, 3 years and at 5 years.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Ipsilateral breast tumour recurrence (IBTR) measured using patient records at 5 years

Key secondary outcome(s))

- 1. Patient-reported acute radiotherapy adverse effects, with a focus on skin, breast, and oesophageal effects, are measured using PRO-CTCAE and trial-specific questionnaires at baseline, weekly for 7 weeks from the start of radiotherapy, and at 3 months
- 2. Patient-reported late effects on quality of life, with a focus on breast symptoms and shoulder

/arm functioning, are measured using EORTC QLQ BR-23 and trial-specific questionnaires at baseline, weeks 1, 3, and 5 from the start of radiotherapy, and at 3 months, 1, 2, 3, 4, and 5 years 3. Patient-reported fatigue is measured using EORTC QLQ FA-12 at baseline, weeks 1, 3, and 5 from the start of radiotherapy, and at 3 months, 1, 2, 3, 4, and 5 years

- 4. Health-related quality of life is measured using EORTC QLQ C-30 and EQ5D-5L at baseline, weeks 1, 3, and 5 from the start of radiotherapy, and at 3 months, 1, 2, 3, 4, and 5 years
- 5. Body image is measured using the Body Image Scale (BIS) at baseline, weeks 1, 3, and 5 from the start of radiotherapy, and at 3 months, 1, 2, 3, 4, and 5 years
- 6. Clinician-reported acute radiotherapy adverse effects, with a focus on skin, oesophageal, and lung toxicity, are measured using CTCAE v5.0 and RTOG at baseline, weekly for 7 weeks from the start of radiotherapy, and at 3 months
- 7. Clinician-reported breast oedema is measured using trial-specific tools at baseline, weekly for 7 weeks from the start of radiotherapy, and at 3 months
- 8. Clinician-reported late radiotherapy adverse effects, with a focus on normal tissue effects and cosmesis, are measured using tools developed in previous breast radiotherapy trials and the Harvard-Harris scale at baseline, 3 months, 1, 3, and 5 years
- 9. Clinician-reported lung toxicity is measured using RTOG at baseline, 3 months, 1, 3, and 5 years 10. Recurrence-free survival, breast cancer-related survival, and overall survival are measured using NHS routinely collected data at baseline, 3 months, 1, 3, and 5 years
- 11. Cost-effectiveness is measured using health economic analysis incorporating data on patient-reported health resource use, out-of-pocket expenses, and health status (EQ5D-5L) at baseline, 3 months, 1, 3, and 5 years

Completion date

30/09/2033

Eligibility

Key inclusion criteria

- 1. Age >=18 years
- 2. Histologically confirmed breast cancer (T1-T3, N0-3, M0) (multifocal disease is allowed) requiring a tumour bed boost plus whole breast radiotherapy +/- radiotherapy to nodes* (axilla +/- internal mammary chain) or DCIS (Tis, N0-3, M0) requiring a tumour bed boost according to local centre policy
- 3. Treated with breast conservation surgery
- 4. Complete microscopic resection (invasive cancer and/or DCIS clear of ink on radial margins or, if at margin, surgeon confirms no further breast tissue to excise)
- 5. Patient can provide informed consent
- * Axilla levels as per MDM recommendation

NB Patients with synchronous bilateral breast cancer can be included as long as the disease on at least one side fulfils the inclusion criteria above. Where the patient has synchronous bilateral disease and needs a tumour bed boost on both sides, both sides will need to fulfil the inclusion criteria for the patient to be eligible for the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

- 1. Treated with ipsilateral mastectomy
- 2. Previous radiotherapy to ipsilateral chest area that precludes delivery of a radical dose of adjuvant radiotherapy to the breast with tumour bed boost. NB for any scenarios where there is overlap with previous radiotherapy approval must be sought from the FAST-Forward Boost trial team prior to randomisation
- 3. Presence of metastatic disease
- 4. Unavailable for any trial related follow-up
- 5. History of malignancy except non-melanomatous skin cancer, CIS cervix, previously unirradiated precancerous changes in the breast (including ductal carcinoma in-situ and lobular carcinoma in-situ), and non-breast malignancy if curative intent and at least 5 years disease free
- 6. Pregnant and/or currently breast feeding
- 7. Participating in the PARABLE trial

Date of first enrolment

01/04/2025

Date of final enrolment

30/09/2028

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Wales

Ireland

Study participating centre Royal Marsden Hospital

Roval Marsden Hospital Downs Road

Sutton United Kingdom SM2 5PT

Study participating centre The Royal Marsden Hospital (london)

Fulham Road London United Kingdom SW3 6JJ

Study participating centre The Christie

550 Wilmslow Road Withington Manchester United Kingdom M20 4BX

Study participating centre Addenbrookes

Addenbrookes Hospital Hills Road Cambridge United Kingdom CB2 0QQ

Study participating centre Beatson West of Scotland Cancer Centre

1053 Great Western Road Glasgow United Kingdom G12 0YN

Study participating centre Belfast City Hospital

51 Lisburn Rd Belfast United Kingdom BT9 7AB

Study participating centre Bristol Haematology & Oncology Centre

Horfield Road Bristol United Kingdom BS2 8ED

Study participating centre Charing Cross Hospital

Fulham Palace Road London United Kingdom W6 8RF

Study participating centre Cheltenham General Hospital

Sandford Road Cheltenham United Kingdom GL53 7AN

Study participating centre Churchill Hospital

Churchill Hospital Old Road Headington Oxford United Kingdom OX3 7LE

Study participating centre Clatterbridge Cancer Centre

Clatterbridge Hospital Clatterbridge Road Wirral United Kingdom CH63 4JY

Study participating centre

Derriford Hospital

Derriford Road Crownhill Plymouth United Kingdom PL6 8DH

Study participating centre Colchester General Hospital

Turner Road Colchester United Kingdom CO4 5JL

Study participating centre Guys Hospital

Guys Hospital Great Maze Pond London United Kingdom SE1 9RT

Study participating centre Ipswich Hospital

Heath Road Ipswich United Kingdom IP4 5PD

Study participating centre South Tees Hospitals NHS Foundation Trust

James Cook University Hospital Marton Road Middlesbrough United Kingdom TS4 3BW

Study participating centre Leicester Royal Infirmary

Infirmary Square Leicester United Kingdom LE1 5WW

Study participating centre United Lincolnshire Teaching Hospitals NHS Trust

Lincoln County Hospital Greetwell Road Lincoln United Kingdom LN2 5QY

Study participating centre Mount Vernon Hospital

Rickmansworth Road Northwood United Kingdom HA6 2RN

Study participating centre Musgrove Park Hospital (taunton)

Musgrove Park Hospital Taunton United Kingdom TA1 5DA

Study participating centre Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane Colney Norwich United Kingdom NR4 7UY

Study participating centre Glan Clwyd General Hospital NHS Trust

Ysbyty Glan Clwyd Sarn Lane Bodelwyddan United Kingdom LL18 5UJ

Study participating centre Nottingham University Hospitals NHS Trust - City Campus

Nottingham City Hospital Hucknall Road Nottingham United Kingdom NG5 1PB

Study participating centre Peterborough City Hospital

Edith Cavell Campus
Bretton Gate
Bretton
Peterborough
United Kingdom
PE3 9GZ

Study participating centre Queen Alexandras Hospital

Southwick Hill Road Cosham Portsmouth United Kingdom PO6 3LY

Study participating centre

Barking, Havering and Redbridge University Hospitals NHS Trust

Queens Hospital Rom Valley Way Romford United Kingdom RM7 0AG

Study participating centre Royal Berkshire Hospital

London Road Reading United Kingdom RG1 5AN

Study participating centre Royal Devon University Healthcare NHS Foundation Trust

Royal Devon University NHS Ft Barrack Road Exeter United Kingdom EX2 5DW

Study participating centre Royal Free London NHS Foundation Trust

Royal Free Hospital Pond Street London United Kingdom NW3 2QG

Study participating centre Lancashire Teaching Hospitals NHS Foundation Trust

Royal Preston Hospital Sharoe Green Lane Preston United Kingdom PR2 9HT

Study participating centre Royal Surrey County Hospital Guildford

Egerton Road Guildford United Kingdom GU2 7XX

Study participating centre

Brighton and Sussex University Hospitals NHS Trust

Royal Sussex County Hospital Eastern Road Brighton United Kingdom BN2 5BE

Study participating centre

Singleton Hospital

Sketty Lane Sketty Swansea United Kingdom SA2 8QA

Study participating centre University Hospital Southampton NHS Foundation Trust

Southampton General Hospital Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Barts and the London NHS Trust

The Royal London Hospital Whitechapel London United Kingdom E1 1BB

Study participating centre Leeds Teaching Hospitals NHS Trust

St. James's University Hospital Beckett Street Leeds United Kingdom LS9 7TF

Study participating centre

University Hospitals Coventry and Warwickshire NHS Trust

Walsgrave General Hospital Clifford Bridge Road Coventry United Kingdom CV2 2DX

Study participating centre

Velindre Cancer Centre

Velindre Road Cardiff United Kingdom CF14 2TL

Study participating centre Western General Hospital

Crewe Road South Edinburgh Lothian United Kingdom EH4 2XU

Study participating centre Weston Park Hospital NHS Trust

Whitham Road Sheffield United Kingdom S10 2SJ

Study participating centre Worcestershire Acute Hospitals NHS Trust

Worcestershire Royal Hospital Charles Hastings Way Worcester United Kingdom WR5 1DD

Sponsor information

Organisation

Institute of Cancer Research

ROR

https://ror.org/00dpztj76

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added Peer reviewe	d? Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025 No	Yes